315 related articles for article (PubMed ID: 25564255)
41. Polymeric Nanocarriers: A New Horizon for the Effective Management of Breast Cancer.
Khan I; Kumar H; Mishra G; Gothwal A; Kesharwani P; Gupta U
Curr Pharm Des; 2017; 23(35):5315-5326. PubMed ID: 28875848
[TBL] [Abstract][Full Text] [Related]
42. Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy.
Kim B; Shin J; Wu J; Omstead DT; Kiziltepe T; Littlepage LE; Bilgicer B
J Control Release; 2020 Jun; 322():530-541. PubMed ID: 32276005
[TBL] [Abstract][Full Text] [Related]
43. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
44. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
45. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
47. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Ito Y
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
[No Abstract] [Full Text] [Related]
48. Biodegradable nanoparticles for targeted ultrasound imaging of breast cancer cells in vitro.
Liu J; Li J; Rosol TJ; Pan X; Voorhees JL
Phys Med Biol; 2007 Aug; 52(16):4739-47. PubMed ID: 17671332
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
[TBL] [Abstract][Full Text] [Related]
50. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
51. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
[TBL] [Abstract][Full Text] [Related]
52. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
53. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.
Colombo M; Corsi F; Foschi D; Mazzantini E; Mazzucchelli S; Morasso C; Occhipinti E; Polito L; Prosperi D; Ronchi S; Verderio P
Pharmacol Res; 2010 Aug; 62(2):150-65. PubMed ID: 20117211
[TBL] [Abstract][Full Text] [Related]
54. Nanocarriers for cancer-targeted drug delivery.
Kumari P; Ghosh B; Biswas S
J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
[TBL] [Abstract][Full Text] [Related]
55. Advances and Implications in Nanotechnology for Lung Cancer Management.
Sarkar S; Osama K; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Akhtar S
Curr Drug Metab; 2017; 18(1):30-38. PubMed ID: 27842486
[TBL] [Abstract][Full Text] [Related]
56. Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Teplinsky E; Esteva FJ
Curr Oncol Rep; 2015 Oct; 17(10):46. PubMed ID: 26314739
[TBL] [Abstract][Full Text] [Related]
57. Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.
Gebhart G; Flamen P; De Vries EG; Jhaveri K; Wimana Z
J Nucl Med; 2016 Feb; 57 Suppl 1():81S-8S. PubMed ID: 26834107
[TBL] [Abstract][Full Text] [Related]
58. Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer.
Dubey SK; Kali M; Hejmady S; Saha RN; Alexander A; Kesharwani P
Eur J Pharm Sci; 2021 Sep; 164():105890. PubMed ID: 34087355
[TBL] [Abstract][Full Text] [Related]
59. Nano-formulations of drugs: Recent developments, impact and challenges.
Jeevanandam J; Chan YS; Danquah MK
Biochimie; 2016; 128-129():99-112. PubMed ID: 27436182
[TBL] [Abstract][Full Text] [Related]
60. [HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Mihály Z; Gyõrffy B
Magy Onkol; 2013 Sep; 57(3):147-56. PubMed ID: 24107820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
